Drugs / Bone marrow-derived mesenchymal stromal cells (MSCs)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05559801 | Jan 2027 → Jan 2029 expected | osteogenesis imperfecta type 3 | Emory University | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bone marrow-derived mesenchymal stromal cells (MSCs) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05559801 ↗ |
| Modality | Cell therapy | “allogeneic (third party), bone-marrow derived mesenchymal stromal cells (MSCs) for the treatment of Osteogenesis Imperfecta (OI) Type 3” NCT05559801 ↗ |
| Route | Intravenous | “MSCs will be infused through IV every 4 months for 6 total infusions.” NCT05559801 ↗ |